Cargando…

Efficacy and safety of prolonged-release melatonin in insomnia patients with diabetes: a randomized, double-blind, crossover study

BACKGROUND: Diabetes is a major comorbidity in insomnia patients. The efficacy and safety of prolonged-release melatonin 2 mg in the treatment of glucose, lipid metabolism, and sleep was studied in 36 type 2 diabetic patients with insomnia (11 men, 25 women, age 46–77 years). METHODS: In a randomize...

Descripción completa

Detalles Bibliográficos
Autores principales:	Garfinkel, Doron, Zorin, Mariana, Wainstein, Julio, Matas, Zipora, Laudon, Moshe, Zisapel, Nava
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2011
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3160855/ https://www.ncbi.nlm.nih.gov/pubmed/21887103 http://dx.doi.org/10.2147/DMSO.S23904

Ejemplares similares

Prolonged-release melatonin for insomnia – an open-label long-term study of efficacy, safety, and withdrawal
por: Lemoine, Patrick, et al.
Publicado: (2011)

Nightly treatment of primary insomnia with prolonged release melatonin for 6 months: a randomized placebo controlled trial on age and endogenous melatonin as predictors of efficacy and safety
por: Wade, Alan G, et al.
Publicado: (2010)

Effect of melatonin on nocturnal blood pressure: meta-analysis of randomized controlled trials
por: Grossman, Ehud, et al.
Publicado: (2011)

Prolonged release melatonin for improving sleep in totally blind subjects: a pilot placebo-controlled multicenter trial
por: Roth, Thomas, et al.
Publicado: (2015)

Add-on prolonged-release melatonin for cognitive function and sleep in mild to moderate Alzheimer’s disease: a 6-month, randomized, placebo-controlled, multicenter trial
por: Wade, Alan G, et al.
Publicado: (2014)

Efficacy and safety of prolonged-release melatonin for insomnia in middle-aged and elderly patients with hypertension: a combined analysis of controlled clinical trials
por: Lemoine, Patrick, et al.
Publicado: (2012)

Long-Term Efficacy and Safety of Pediatric Prolonged-Release Melatonin for Insomnia in Children with Autism Spectrum Disorder
por: Maras, Athanasios, et al.
Publicado: (2018)

Lasting treatment effects in a postmarketing surveillance study of prolonged-release melatonin
por: Hajak, Göran, et al.
Publicado: (2015)

Sleep, Growth, and Puberty After 2 Years of Prolonged-Release Melatonin in Children With Autism Spectrum Disorder
por: Malow, Beth A., et al.
Publicado: (2020)

New perspectives on the role of melatonin in human sleep, circadian rhythms and their regulation
por: Zisapel, Nava
Publicado: (2018)

Pediatric Prolonged-Release Melatonin for Sleep in Children with Autism Spectrum Disorder: Impact on Child Behavior and Caregiver’s Quality of Life
por: Schroder, Carmen M., et al.
Publicado: (2019)

New approaches in the management of insomnia: weighing the advantages of prolonged-release melatonin and synthetic melatoninergic agonists
por: Hardeland, Rüdiger
Publicado: (2009)

Dynamic Changes in Neurexins' Alternative Splicing: Role of Rho-Associated Protein Kinases and Relevance to Memory Formation
por: Rozic, Gabriela, et al.
Publicado: (2011)

PT655. The effectiveness of prolonged-release melatonin among primary insomnia patients whose sleep schedule was set
por: Park, Boram, et al.
Publicado: (2016)

Therapeutic Effects of Melatonin Receptor Agonists on Sleep and Comorbid Disorders
por: Laudon, Moshe, et al.
Publicado: (2014)

Bioavailability of Oniria(®), a Melatonin Prolonged-Release Formulation, Versus Immediate-Release Melatonin in Healthy Volunteers
por: Román Martinez, Manuel, et al.
Publicado: (2022)

Melatonin, but not melatonin receptor agonists Neu-P11 and Neu-P67, attenuates TNBS-induced colitis in mice
por: Zielińska, Marta, et al.
Publicado: (2016)

Efficacy and hypnotic effects of melatonin in shift-work nurses: double-blind, placebo-controlled crossover trial
por: Sadeghniiat-Haghighi, Khosro, et al.
Publicado: (2008)

Efficacy of Prolonged-Release Melatonin 2 mg (PRM 2 mg) Prescribed for Insomnia in Hospitalized Patients for COVID-19: A Retrospective Observational Study
por: Bologna, Carolina, et al.
Publicado: (2021)

The Efficacy of Oral Melatonin in Improving Sleep in Cancer Patients with Insomnia: A Randomized Double-Blind Placebo-Controlled Study
por: Kurdi, Madhuri S, et al.
Publicado: (2016)

Prolonged–release melatonin in patients with idiopathic REM sleep behavior disorder
por: Jun, Jin‐Sun, et al.
Publicado: (2019)

Prolonged–release melatonin in patients with idiopathic REM sleep behavior disorder
Publicado: (2019)

Effects of melatonin prolonged-release on both sleep and motor symptoms in Parkinson’s disease: a preliminary evidence
por: Liguori, Claudio, et al.
Publicado: (2022)

Effect of Acupuncture on Pregnancy-Related Insomnia and Melatonin: A Single-Blinded, Randomized, Placebo-Controlled Trial
por: Foroughinia, Saeedeh, et al.
Publicado: (2020)

Effects of Melatonin on Glycemic Variability in Type 2 Diabetes Mellitus: Protocol for a Crossover, Double-Blind, Placebo-Controlled Trial
por: Martorina, Wagner, et al.
Publicado: (2023)

Melatonin for Insomnia in Medical Inpatients: A Narrative Review
por: Salahub, Christine, et al.
Publicado: (2022)

Melatonin Treatment for Pediatric Patients with Insomnia: Is There a Place for It?
por: Rolling, Julie, et al.
Publicado: (2022)

Dissolution of Intact, Divided and Crushed Circadin Tablets: Prolonged vs. Immediate Release of Melatonin
por: Chua, Hui Ming, et al.
Publicado: (2016)

Effectiveness of NexQuest Natural Frequency Technology(®) on sleep and mood of adults with insomnia symptoms: a randomized, double blind and placebo controlled crossover trial
por: Hooper, Stephanie, et al.
Publicado: (2020)

Bioavailability of Melatonin after Administration of an Oral Prolonged-Release Tablet and an Immediate-Release Sublingual Spray in Healthy Male Volunteers
por: Ait Abdellah, Samira, et al.
Publicado: (2023)

Results of a randomized, double blind, placebo controlled, crossover trial of melatonin for treatment of Nocturia in adults with multiple sclerosis (MeNiMS)
por: Drake, Marcus J., et al.
Publicado: (2018)

Protocol for a randomized, double blind, placebo controlled, crossover trial of Melatonin for treatment of Nocturia in adults with Multiple Sclerosis (MeNiMS)
por: Delgado, D., et al.
Publicado: (2017)

Zolpidem modified-release in insomnia
por: Kirkwood, Cynthia, et al.
Publicado: (2007)

Glycemic Variability in Patients with Type 2 Diabetes Mellitus (T2DM): The Role of Melatonin in a Crossover, Double-Blind, Placebo-Controlled, Randomized Study
por: Martorina, Wagner, et al.
Publicado: (2023)

The Effects of Magnesium – Melatonin - Vit B Complex Supplementation in Treatment of Insomnia
por: Djokic, Gorica, et al.
Publicado: (2019)

Refractory Insomnia in an Adolescent with Total Blindness
por: Tubbs, Andrew S., et al.
Publicado: (2019)

ACTH and cortisol responses to CRH in acute, subacute, and prolonged critical illness: a randomized, double-blind, placebo-controlled, crossover cohort study
por: Peeters, Bram, et al.
Publicado: (2018)

Aspartame Sensitivity? A Double Blind Randomised Crossover Study
por: Sathyapalan, Thozhukat, et al.
Publicado: (2015)

Melatonin Supplementation for Six Weeks Had No Effect on Arterial Stiffness and Mitochondrial DNA in Women Aged 55 Years and Older with Insomnia: A Double-Blind Randomized Controlled Study
por: Kim, Yonghwan, et al.
Publicado: (2021)

Dose finding of melatonin for chronic idiopathic childhood sleep onset insomnia: an RCT
por: van Geijlswijk, Ingeborg M., et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_d4toh1j6d2he53pbqq9nopk98j